Meanwhile, HER2 gene amplification and receptor overexpression, observed in approximately 15% to 20% of breast cancer patients, also serve as significant prognostic markers associated with poor outcomes, including more aggressive disease and shorter survival [5]. This evidence concerns the gene ERBB2 and breast cancer.